Aug 22 (Reuters) - Chugai Pharmaceutical Co Ltd:
* CHUGAI PHARMACEUTICAL - TECENTRIQ RECEIVES APPROVAL FOR ADDITIONAL INDICATION OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER FROM JAPAN’S MHLW
* CHUGAI PHARMACEUTICAL CO LTD-BASED ON RESULTS FROM PHASE I/III IMPOWER133 STUDY, TECENTRIQ WITH CHEMOTHERAPY MET PRIMARY ENDPOINT OF OVERALL SURVIVAL Source text (bit.ly/2zhtTDX) Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.